Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 13/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.41 |
| ▸ | RPLP1 | P05386 | 5/20 | 0.41 |
| ▸ | RPLP0 | P05388 | 5/20 | 0.41 |
| ▸ | RPS17 | P08708 | 5/20 | 0.41 |
| ▸ | RPSA | P08865 | 5/20 | 0.41 |
| ▸ | RPS2 | P15880 | 5/20 | 0.41 |
| ▸ | RPL35A | P18077 | 5/20 | 0.41 |
| ▸ | RPL7 | P18124 | 5/20 | 0.41 |
| ▸ | RPL17 | P18621 | 5/20 | 0.41 |
| ▸ | RPS4Y1 | P22090 | 5/20 | 0.41 |
| ▸ | RPS3 | P23396 | 5/20 | 0.41 |
| ▸ | RPS12 | P25398 | 5/20 | 0.41 |
| ▸ | RPL13 | P26373 | 5/20 | 0.41 |
| ▸ | RPL10 | P27635 | 5/20 | 0.41 |
| ▸ | RPL12 | P30050 | 5/20 | 0.41 |
| ▸ | RPL9; RPL9P7; RPL9P8; RPL9P9 | P32969 | 5/20 | 0.41 |
| ▸ | RPL22 | P35268 | 5/20 | 0.41 |
| ▸ | RPL4 | P36578 | 5/20 | 0.41 |
| ▸ | RPS19 | P39019 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12454039 | 0.86 | PCSK9 (0.40) | PCSK9KCNH2RPLP1RPLP0RPS17 | |
| SCHEMBL2232132 | 0.85 | PCSK9 (0.40) | PCSK9KCNH2RPLP1RPLP0RPS17 | |
| SCHEMBL2232135 | 0.85 | PCSK9 (0.40) | PCSK9KCNH2RPLP1RPLP0RPS17 | |
| SCHEMBL2350007 | 0.80 | JAK3 (0.44) | JAK3 | |
| SCHEMBL12346476 | 0.77 | JAK3 (0.47) | JAK3 | |
| SCHEMBL2231093 | 0.77 | CDK7 (0.48) | FLT3CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL2231095 | 0.77 | CDK7 (0.48) | FLT3CCNT1CCNKCCNE1CDK2 | |
| SCHEMBL2233927 | 0.76 | JAK2 (0.56) | KCNH2JAK3 | |
| SCHEMBL2233296 | 0.76 | PRMT5 (0.44) | CCNKCDK12JAK3 | |
| SCHEMBL12454266 | 0.72 | PIM1 (0.38) | CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-9206183-B2 | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-12-08 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL SA (ES) | 2015-04-30 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2014-03-27 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | BACH TANA JORDI (ES) | 2013-08-15 | — | — | US | disclosed |
| WO-2011101161-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-08-25 | — | — | WO | disclosed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | disclosed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118186-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PCSK9 3463/4885KCNH2 2973/4885RPLP1 1909/4885 |
| US-20130209400-A1 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PCSK9 3711/4885KCNH2 2443/4885RPLP1 1916/4885 |
| US-20140086870-A9 | PYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PCSK9 3711/4885KCNH2 2443/4885RPLP1 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.